Israeli clinical study offers hope to ALS patients

Could enhanced adult stem cells halt the progression of a neurological disease for which there is no treatment or cure?

The famous physicist Stephen Hawking has lived with the progressive neuro-muscular disease ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) for decades. But ordinarily, the disease usually causes death within five years, as patients gradually lose the ability to move, swallow and breathe.

Since there is no known cure for ALS, it’s little wonder that patients from across the globe are clamoring to be included in a groundbreaking clinical study started recently at Jerusalem’s Hadassah University Medical Center. Researchers are looking at the ability of enhanced autologous stem cells (taken from the patients’ own bone marrow) to stop the progression of ALS and perhaps even improve the condition of sufferers.

However, there are only 24 slots available in the year-long study, says Prof. Dimitrios Karussis, the renowned stem-cell transplant expert leading the research.

Karussis, head of Hadassah’s Multiple Sclerosis Center and a member of the European Steering Committee for Bone Marrow Transplantation in Multiple Sclerosis, is a stem-cell therapy pioneer. Last year, findings of his research published in the journal Archives of Neurology demonstrated that autologous stem cells safely stopped disease progression for several months in both multiple sclerosis (MS) and ALS patients.

Bone marrow is the body’s greatest source of adult stem cells. Hematopoietic stem cells, which continuously produce and renew white and red blood cells, have long been used to treat blood disorders such as lymphoma and leukemia. The more recently discovered mesenchymal stem cells (MSC) are the ones harvested for Karussis’ studies, because they can produce almost all kinds of tissues and differentiated cells, including cells of the central nervous system.

“This is a unique protocol in the Western world,” Karussis tells ISRAEL21c.

Helping muscles and nerves communicate

The current Hadassah study is a collaboration with Petah Tikvah-based BrainStorm Cell Therapeutics, which is commercializing a technique innovated at Tel Aviv University for growing and modifying adult stem cells to treat ALS.

Dr. Dimitrios Karussis

Dr. Dimitrios Karussis: “This is a unique protocol in the Western world.”

“We take bone marrow from ALS patients and grow it in sterile conditions at Hadassah. In one month, a few cells grow to 100 million cells,” BrainStorm’s acting CEO Adrian Harel tells ISRAEL21c. “Our ‘trick’ is causing the cells to differentiate so that they secrete proteins that are important for communication between muscles and nerves. Scientists think that in ALS there is a discontinuation of communication between muscle and nerve.”

The specially modified stems cells, called NurOwn, are being injected into 12 newly diagnosed and 12 more advanced patients.

“This clinical study is very important for patients and for their families,” says Harel, “because it gives hope that doesn’t exist right now.”

Former American prize fighter Muhammad Ali’s daughter, Rasheda, sits on BrainStorm’s advisory board and was interviewed recently about Karussis’ study using NurOwn. Ali is following it closely for its implications for people with Parkinson’s disease, like her dad, and those with other neuro-degenerative diseases.

“We have to show that this treatment is safe and has no side effects, and also that it stops degradation of the disease, which normally progresses quickly,” says Harel. “We also would like to show that there is improvement in function.”

The biggest hope in the field

Israeli ALS activist Avichai Kremer of prize4life and of the Israeli ALS Association was the first person to receive experimental injections of NurOwn at Hadassah last October. He reported nearly three months later that the treatment seemed to stop the progression of his ALS and improved his breathing and speaking.


Bone marrow lab

Photo by Yossi Zamir/Flash90
The bone marrow lab at Hadassah University Medical Center.

Harel said he and Karussis “are being bombarded with letters and calls from the US, Europe and also Arab countries” from patients wishing to learn more about NurOwn. ALS patients number about 750 In Israel and 30,000 in North America at any given time.

Harvard Medical School neurologist Robert H. Brown Jr. visited Karussis in March, and is preparing to do similar clinical research at the Neuromuscular Research Laboratory at Massachusetts General Hospital.

Karussis stresses that using autologous stem cells is ideal since there is no need to find donors and no concern about the ethical problems that arise from the use of embryonic stem cells.

“In ALS, until now there has been no effective treatment, nothing even close, to arrest progression,” Karussis stresses. “This is definitely the biggest hope now in this field.”

Related Articles

About Abigail Klein Leichman

Abigail Klein Leichman is a writer and associate editor at ISRAEL21c. Prior to moving to Israel in 2007, she was a specialty writer and copy editor at a daily newspaper in New Jersey and has freelanced for a variety of newspapers and periodicals since 1984.
  • Larry Cartier

    If NurOwn represents the best hope now for ALS patients , wouldn’t it be merciful and miraculous for numerous reputable teaching hospitals throughout the world to receive this new technique now ; and then , offer it to ALS patients willing to try NurOwn now ?

    If world numerous world governments , organizations , corporations , etc. can waste billions upon billions of dollars in countless , useless ways , why not spend some money on a humanitarian cause that would offer life hope to tens of thousands of suffering people ?

  • Ricardo

    There are also Stem Cells in the fat. There are some Stem Cell therapies for ALS patients that come from a light pressure liposuccion and then the Stem Cells are inyected. There have been some good results.

  • Barbara Williams

    Why must those
    with this disease wait to have access to this
    treatment? Our global protocols for bringing products or treatment options to
    market for incurable diseases are TOO slow and do NOT take the
    patients/families perspective into consideration. Technology is advancing at
    lightning speed but in these situations, our systems to utilize these
    technologies to their fullest potential remains stuck in the past. Of course
    there is a need to protect patients from charlatans and unsafe treatments but
    with results like we are seeing here, why can’t these trials be accelerated
    (rapidly) and made available to those who are dying? The whole process needs to
    be revamped and that should start with equal weight give to input from patients
    and their families!!

  • Pingback: Israeli Top Ten Advances Against Alzheimer’s Disease |

  • christine ann chisman

    Is NurOwn available as a treatment for ALS, in Israel, in Europe perhaps? – my son has the illness – or is it still at clinical study level, this I wonder. If anyone can help me, my email is registered – I don’t have much time left, grateful for any help.